Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
F18-PSMA
- Development stage
- Unknown
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
F18-PSMA (Fluorine-18 labeled prostate-specific membrane antigen) refers to a class of radiolabeled small-molecule targeting ligands used as diagnostic imaging agents in positron emission tomography (PET) scans. These agents specifically bind to prostate-specific membrane antigen (PSMA), a type II transmembrane glycoprotein that is highly overexpressed on the surface of prostate cancer cells. By incorporating the positron-emitting radioisotope fluorine-18 (18F), F18-PSMA tracers allow for high-resolution, sensitive visualization of primary and metastatic prostate cancer lesions, including pelvic lymph nodes and bone metastases. This class includes several specific diagnostic agents such as 18F-DCFPyL (piflufolastat F-18), 18F-PSMA-1007, and 18F-rhPSMA-7.3 (flotufolastat F-18), which are widely utilized for the initial staging of high-risk prostate cancer and the localization of biochemical recurrence.
- Other names
- 18F-PSMA18F-labeled PSMAF-18-PSMAF18-PSMAF 18-PSMAFluorine-18 PSMAFluorine18 PSMAFluorine 18 PSMAFluorine-18 labeled prostate specific membrane antigenFluorine18 labeled prostate specific membrane antigenFluorine 18 labeled prostate specific membrane antigen
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on F18-PSMA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on F18-PSMA.